A new type of diagnostic system using sophisticated computer software
capable of analyzing and comparing cancerous tissue against a vast
databank of digital images of cancer samples could speed up treatment
for ovarian cancer.
The system, being designed by Aïcha BenTaieb, a
Simon Fraser University computing science PhD student, aims to automate
the identification of ovarian carcinomas for a more reliable, faster
and available diagnosis. What is known is that there are five main subtypes. Effective
treatment depends on identifying the subtype as soon as possible. But
current methods are subjective, time-consuming and prone to error. Using information collated via computers, BenTaieb believes she has found a better way to identify these subtypes. Each
ovarian cancer subtype shows individual structural and cellular
characteristics. For treatment to be effectively targeted, the subtype
must first be identified.
Currently, pathologists analyze tissue samples using a microscope, digital scanner and computer software. However, identification can easily be impaired by technical factors such as lighting and the pathologist’s experience.
With BenTaieb’s method, an artificial intelligence feature is
integrated into the software that helps the pathologist analyze the
tissue sample. This feature is trained, through a large dataset of
expert annotated slides, to automatically identify the characteristic
visual patterns for each subtype of carcinoma.
“We’re looking at
the whole image, in different regions, in a more efficient way, using
computers to extract image-based features,” BenTaieb said.
This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment